Polarean Imaging Receives FDA Approval to Expand XENOVIEW Indication
Polarean Imaging plc, a pioneer in advanced medical imaging technology, has exciting news regarding its innovative solution, XENOVIEW. Recently, the US Food and Drug Administration (FDA) granted approval for Polarean’s Supplemental New Drug Application, allowing XENOVIEW to be used in children as young as six years old. This significant expansion lowers the previous age limit, broadening access to vital imaging technology for an additional one million pediatric patients.
Enhancing Access to Lung Imaging for Younger Patients
The newly approved use of XENOVIEW allows medical professionals to conduct Magnetic Resonance Imaging (MRI) evaluations for lung ventilation in both adults and children starting from six years old. This change is monumental for healthcare providers as it introduces new XENOVIEW Dose Delivery Bags specifically designed for younger patients. The inclusion of varying bag sizes demonstrates Polarean’s commitment to tailoring solutions that meet the specific needs of its diverse patient population.
Statements from Company Leaders
Christopher von Jako, Ph.D., the Chief Executive Officer of Polarean, expressed joy at the FDA’s decision. He remarked, "We are thrilled to receive the FDA's approval for our Supplemental NDA, allowing us to extend our technology to younger pediatric patients. This enhances our clinical utility and broadens the scope of our technology, making it a powerful tool for healthcare professionals treating chronic respiratory conditions in children. Our aim is to improve patient outcomes significantly, and we are eager to launch a controlled U.S. market release of the pediatric Dose Delivery Bags, starting with Cincinnati Children’s Hospital."
Expert Insights on the Impact of the Approval
Dr. Erik Hysinger, a Pediatric Pulmonologist at Cincinnati Children’s, shared his enthusiasm regarding this development. He mentioned, "This approval is a remarkable advancement for diagnosing and monitoring chronic lung diseases in children such as asthma, cystic fibrosis, and others. Having the capability to conduct advanced imaging on younger patients equips clinicians with the necessary tools to assess disease progression and response to treatments more effectively. This is a significant stride towards personalized healthcare for these young individuals struggling with respiratory issues."
About Polarean Imaging plc
Polarean Imaging has established itself as a leader in the medical imaging realm, particularly focusing on respiratory health. The company’s core mission revolves around optimizing lung function assessment, particularly for the over 500 million people worldwide battling chronic respiratory diseases. By leveraging the non-invasive and radiation-free capabilities of MRI with its unique hyperpolarized contrast agent, XENOVIEW, Polarean is set on redefining the landscapes of pulmonary diagnostics.
Understanding the Technology Behind XENOVIEW
XENOVIEW is specifically indicated for MRI evaluation of lung ventilation. It is crafted from a hyperpolarized gas blend, enhancing visibility and accuracy during imaging procedures. With a commitment to continue innovating, Polarean Imaging constantly explores new avenues for improving patient care and clinical outcomes.
Committed to Continuous Improvement and Innovation
Since its inception in 2012, Polarean Imaging plc has dedicated itself to the pursuit of managing chronic respiratory diseases through technology. The recent expansion of its XENOVIEW technology to include pediatric patients reflects its mission to provide modern and effective solutions in the realm of lung health.
Frequently Asked Questions
What is XENOVIEW?
XENOVIEW is a hyperpolarized contrast agent used in MRI to evaluate lung ventilation, particularly beneficial for both adults and children starting at six years of age.
Who will benefit from the expanded indication of XENOVIEW?
The expanded age indication benefits approximately one million pediatric patients who may require lung ventilation assessments, allowing for better diagnosis and management of chronic respiratory diseases.
How does XENOVIEW work?
XENOVIEW utilizes a hyperpolarized gas, enhancing the visibility of lung images during MRI scans, which allows for accurate evaluations of lung function.
What are the expected outcomes of using XENOVIEW in younger patients?
The expected outcomes include improved diagnosis, monitoring of lung diseases, and a more personalized treatment approach for pediatric patients suffering from chronic respiratory conditions.
Who is the leadership behind Polarean Imaging?
The company is led by Christopher von Jako, Ph.D., who is passionate about advancing pulmonary imaging technology for better patient outcomes across various age groups.
